Design
Review
Answers are grounded in this paper and cite their sources.
Provides a concise overview of key July 2018 heart failure publications, covering prognostic markers, pathophysiology, and clinical trial updates.
A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology (ESC) provides practical recommendations about clinical, laboratory and instrumental monitoring of patients hospitalized for acute heart failure (HF). The indications, timing of assessment and prognostic value of clinical symptoms and signs, laboratory markers and echocardiographic parameters are discussed.1 Biering-Sørensen et al.2 assessed the role of left ventricular ejection time (LVET) for the development of HF in a middle-aged African–Americans cohort of the Atherosclerosis Risk in Communities study (Jackson cohort, n = 1980) who underwent echocardiography between 1993 and 1995. During a median follow-up of 17.6 years, 384 subjects (19%) developed HF, 158 (8%) had a myocardial infarction, and 587 (30%) died. A lower LVET was associated with increased risk of all events and remained an independent predictor of incident HF (hazard ratio 1.07, 95% confidence interval 1.02–1.14; P = 0.010 per 10 ms decrease) after adjustment for age, sex, hypertension, diabetes, body mass index, heart rate, systolic and diastolic blood pressure, fractional shortening and left atrial diameter. Oxygen consumption (VO2) has a direct relationship with work rate during exercise in normal subjects. Popovic et al.3 have defined a flattening VO2 vs. work rate trajectory as a downward inflection >35% of this relationship and assessed its occurrence in 319 patients with HF who underwent cardiopulmonary exercise testing. A flattening VO2 occurred in 92 patients (28.8%) and was an independent predictor of outcomes in a multivariable model including peak VO2, VE/VCO2 slope and exercise oscillatory ventilation. Patients with a flattening VO2 were more likely to have pulmonary hypertension and right ventricular dysfunction suggesting that it may be caused by decreased pulmonary blood flow to the left heart. Packer4 reviews how drugs can have different effects depending on the HF pathophysiology. Statins have no favourable effects in patients with HF and reduced ejection fraction (HFrEF). However, they prevent HF events in subjects with hyperlipidaemia and have anti-inflammatory effects potentially useful for the treatment of HF with preserved ejection fraction (HFpEF), a condition in which cytokine release from epicardial adipocytes may cause fibrosis and diastolic dysfunction.5-8 He then hypothesises that the same may occur with antidiabetic agents. Sodium–glucose co-transporter 2 (SGLT2) inhibitors might have reduced HF events through their anti-inflammatory effects and HFpEF prevention but have no effects in HFrEF.9, 10 Glucagon-like peptide-1 receptor agonists may have neutral effects on HF events in people at risk for HFpEF, but worsen HFrEF.11, 12 LION-HEART (Levosimendan Intermittent administration in Outpatients: effects on Natriuretic peptides in advanced chronic HEART failure) was a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic HF.13 Sixty-nine patients from 12 Spanish centres were randomly assigned 2:1 to levosimendan or placebo. Treatment consisted in a 6 h intravenous infusion (0.2 μg/kg/min without bolus) every 2 weeks for 12 weeks. The area under the curve of the levels of N-terminal pro-B-type natriuretic peptide over time for patients who received levosimendan was significantly lower than for the placebo group (primary endpoint). Compared with the placebo group, the patients on levosimendan had a lower rate of HF hospitalizations and were less likely to experience a decline in health-related quality of life. Adverse event rates were similar in the two treatment groups. These promising results can be the basis for a larger trial.13 The clinical significance of HF with mid-range ejection fraction (HFmrEF), first introduced in the 2016 ESC HF guidelines,14 has become clearer in the last year.15 Abdul-Rahim et al.16 compared the effects of digoxin in patients with HFmrEF vs. those with HFrEF and HFpEF (n = 1195, 5874 and 719, respectively) in the Digitalis Investigation Group (DIG) trial. Event rates in patients with HFmrEF were similar to those in HFpEF and much lower than in HFrEF. Compared with placebo, digoxin reduced HF hospitalizations and the combined events of HF death or HF hospitalization in patients with HFrEF but not in those with HFpEF and its effects were intermediate in those with HFmrEF. Congestion is a major determinant of outcomes in patients with acutely decompensated HF.17 In the primary analysis of the Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF), ultrafiltration (UF) had no greater efficacy on decongestion and was associated with a rise in serum creatinine compared to an aggressive, urine output-guided pharmacological protocol for decongestion.18 However, there was a substantial patient dropout and treatment crossover in this trial. In this per-protocol analysis, only patients of the UF arm who had UF output collected up to 96 h or, if randomized to the pharmacological arm, who had urine, but no UF, output collected up to 96 h, were included.19 This per-protocol analysis showed that, compared with the pharmacological treatment arm, UF was associated with higher cumulative fluid loss (P = 0.003), net fluid loss (P = 0.001), and relative reduction in weight (P = 0.02). It was also associated with higher serum creatinine and blood urea nitrogen by 72 h (P-interaction <0.05 for both), lower serum sodium by 48 h and increased plasma renin activity by 96 h. There were no differences in 60-day outcomes between the two arms.19
No takes yet. Share an insight, caveat, or question.
Marco Metra (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: